A Clinical Trial to Qualify the Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2013
At a glance
- Drugs Dalotuzumab (Primary) ; Ridaforolimus (Primary)
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 28 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.